Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol

Acta Orthopaedica

Volumn 80, Issue SUPPL. 334, 2009, Pages 60-66

  Smeland, Sigbjørn ^a   Bruland, Øyvind S ^b   Hjorth, Lars ^c   Brosjö, Otte ^d   Bjerkehagen, Bodil ^a   Österlundh, Gustaf ^e   Jakobson, Åke ^d   Hall, Kirsten Sundby ^a   Monge, Odd R ^f   Björk, Olle ^d   Alvegaard, Thor A ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; ENTEROCOLITIS; FEBRILE NEUTROPENIA; FEMALE; FINLAND; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIMB SALVAGE; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NORWAY; OSTEOSARCOMA; PATIENT COMPLIANCE; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; SCANDINAVIA; SCHOOL CHILD; SEPTIC SHOCK; SWEDEN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TYPHLITIS; UNSPECIFIED SIDE EFFECT;

EID: 73349126968     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994; 12; 2471-2508
2. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico Rizzoli according to the istituto orotpedico Rizzoli/osteosarcoma-2 protocol: an update report. J Clin Oncol 2000; 18: 4016-4027
3. Bacci G, Forni C, Longhi A, et al. Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a-27-year experience in a single institution. J Surg Oncol 2007; 96: 118-123
4. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer 1993; 72: 3227-3228
5. Bielack S, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790
6. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33: 1725-1731
7. Enneking WF, Spanier S, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; (153): 106-120. (Pubitemid 11217753)
8. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715
9. Ferrari S, Smeland S. Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups J Clin Oncol 2005; 23: 8845-8852
10. Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998; 9: 893-899
11. Huvos AG, Rosen G, Marcove C. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14-18.
12. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568
13. Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patietns treated with intensified chemotherapy:a randomized phase III trial of the European Ostesarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-118
14. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600-1606
15. Meyers P, Schwartz CL, Krail M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamdie and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23: 2004-2011
16. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221-1230
17. Rosen G, Murphy ML, Huvos AG, et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43: 2163-2177
18. Smeland S, Müller C, Alvegaard TA, et al..Scandinavian Sarcoma Group Osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 488-494
19. Saeter G, Alvegård TA, Elomaa I, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766-1775
20. Saeter G, HØie J, Stenwig, AE, et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995; 75: 1084-1093
21. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6: 329-337